Hydroxychloroquine for prevention of abnormal glucose tolerance and diabetes in individuals at-risk for type 1 diabetes mellitus
What is the Hydroxychloroquine Prevention Study?
We are trying to learn more about how to delay or prevent type 1 diabetes. In this study, we are testing hydroxychloroquine (HCQ) to see if treatment with HCQ will result in fewer people developing diabetes, compared to the people in the study who do not receive HCQ.
Who can participate?
- to be at least 3 years old
- have two or more diabetes-related autoantibodies (confirmed by TrialNet screening in last 6 months)
- normal results on an oral glucose tolerance test (OGTT)
- be able to swallow a whole capsule
- NOT be pregnant or planning to become pregnant while in the study
- NOT have any medical conditions that might make it unsafe for you to be in this study
What will study participants be asked to do?
- Come to the University of Florida every six months for visits, which include blood tests, for the duration of your participation in the study.
- Take study capsules as directed
- Have eye exams as needed
- Stick to the required study visit schedule. If you are unable to to travel to University of Florida for a study visit, we may be able to make arrangements for you to have some of your blood test done locally.
Informed Consent available upon request.